A BILL 
To amend titles XVIII and XIX of the Social Security Act 
and title XXVII of the Public Health Service Act to 
provide for coverage of certain drugs used in the treat-
ment or management of a rare disease or condition, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Access to Rare Indica-
4
tions Act of 2021’’. 
5
00:37 Dec 17, 2021
H6160
2 
•HR 6160 IH
SEC. 2. COVERAGE OF CERTAIN DRUGS USED IN TREAT-
1
MENT OR MANAGEMENT OF RARE DISEASE 
2
OR CONDITION. 
3
(a) MEDICARE.— 
4
(1) IN
GENERAL.—Section 1861(t)(2) of the 
5
Social Security Act (42 U.S.C. 1395x(t)(2)) is 
6
amended— 
7
(A) in subparagraph (A), by inserting after 
8
‘‘regimen’’ the following: ‘‘, or in the treatment 
9
or management of a disease or condition affect-
10
ing 200,000 or fewer individuals in the United 
11
States,’’; and 
12
(B) in subparagraph (B)(ii)— 
13
(i) in subclause (I), by striking ‘‘, or’’ 
14
at the end and inserting a semicolon; 
15
(ii) in subclause (II), by striking the 
16
period at the end and inserting ‘‘; or’’; and 
17
(iii) by adding at the end the fol-
18
lowing new subclause: 
19
‘‘(III) in the case of a drug that 
20
is used in the treatment or manage-
21
ment of a disease or condition affect-
22
ing 200,000 or fewer individuals in 
23
the United States, such use is sup-
24
ported by peer-reviewed medical lit-
25
erature, clinical guidelines, or an ex-
26
00:37 Dec 17, 2021
H6160
3 
•HR 6160 IH
pert in such disease or condition as 
1
identified by a medical society in-
2
volved in the treatment or manage-
3
ment of such disease or condition, and 
4
is not reviewed unfavorably in the 
5
compendia 
described 
in 
section 
6
1927(g)(1)(B)(i), or listed as a con-
7
traindication in the FDA-approved la-
8
beling.’’. 
9
(2) MEDICALLY ACCEPTED USES OF COVERED 
10
PART D DRUGS IN TREATING RARE CONDITIONS.— 
11
Section 1860D–2(e)(4)(A) of the Social Security Act 
12
(42 U.S.C. 1395w–104(e)(4)(A)) is amended— 
13
(A) in clause (i)(II), by striking ‘‘and’’; 
14
(B) by redesignating clause (ii) as clause 
15
(iii); and 
16
(C) by inserting after clause (i)(II) the fol-
17
lowing new clause: 
18
‘‘(ii) in the case of a covered part D 
19
drug used in the treatment or management 
20
of a disease or condition affecting 200,000 
21
or fewer individuals in the United States, 
22
in section 1861(t)(2)(B); and’’. 
23
(3) EFFECTIVE DATE.—The amendments made 
24
by this subsection apply with respect to items and 
25
00:37 Dec 17, 2021
H6160
4 
•HR 6160 IH
services furnished on or after the date that is 30 
1
days after the date of the enactment of this Act. 
2
(b) MEDICAID.— 
3
(1) IN GENERAL.—Section 1927(k)(6) of the 
4
Social Security Act (42 U.S.C. 1396r–8(k)(6)) is 
5
amended to read as follows: 
6
‘‘(6) MEDICALLY ACCEPTED INDICATION.—The 
7
term ‘medically accepted indication’ means any use 
8
for a covered drug— 
9
‘‘(A) which is approved under the Federal 
10
Food, Drug, and Cosmetic Act; 
11
‘‘(B) which is supported by one or more ci-
12
tations included or approved for inclusion in 
13
any of the compendia described in subsection 
14
(g)(1)(B)(i); or 
15
‘‘(C) in the case of a drug used to treat or 
16
manage 
a 
disease 
or 
condition 
affecting 
17
200,000 or fewer individuals in the United 
18
States— 
19
‘‘(i) the use of such drug is supported 
20
by peer-reviewed medical literature, clinical 
21
guidelines, or an expert in such disease or 
22
condition as identified by a medical society 
23
involved in the treatment or management 
24
of such disease or condition; and 
25
00:37 Dec 17, 2021
H6160
5 
•HR 6160 IH
‘‘(ii) is not reviewed unfavorably in 
1
the compendia described in subsection 
2
(g)(1)(B)(i), or listed as a contraindication 
3
in the FDA-approved labeling.’’. 
4
(2) 
CONFORMING
AMENDMENT.—Section 
5
1927(d)(4)(C) of the Social Security Act (42 U.S.C. 
6
1396r–8(d)(4)(C)) is amended by striking ‘‘com-
7
pendia’’ and inserting ‘‘sources’’. 
8
(3) EFFECTIVE DATE.—The amendments made 
9
by this subsection apply with respect to covered out-
10
patient drugs furnished on or after the date that is 
11
30 days after the date of the enactment of this Act. 
12
(c) PRIVATE HEALTH INSURANCE.— 
13
(1) IN GENERAL.—Subpart II of part A of title 
14
XXVII of the Public Health Service Act (42 U.S.C. 
15
300gg–11 et seq.) is amended by adding at the end 
16
the following new section: 
17
‘‘SEC. 2730. IN GENERAL COVERAGE OF CERTAIN DRUGS 
18
USED IN TREATMENT OR MANAGEMENT OF A 
19
RARE DISEASE OR CONDITION. 
20
‘‘A group health plan or a health insurance issuer of-
21
fering group or individual health insurance coverage shall 
22
provide a mechanism for expedited formulary exception, 
23
reconsideration, and appeal of any denial of coverage for 
24
a drug or biological— 
25
00:37 Dec 17, 2021
H6160
6 
•HR 6160 IH
‘‘(1) approved by the Food and Drug Adminis-
1
tration; 
2
‘‘(2) for which the use is related to treatment 
3
or management of a disease or condition affecting 
4
200,000 or fewer individuals in the United States; 
5
and 
6
‘‘(3) the use of which is supported by the FDA- 
7
approved label, peer-reviewed literature, clinical 
8
guidelines, or an expert in such disease or condition 
9
as identified by a medical society involved in the 
10
treatment or management of such disease or condi-
11
tion, and that is not reviewed unfavorably in the 
12
compendia described in section 1927(g)(1)(B)(i) of 
13
the Social Security Act or listed as a contraindica-
14
tion in the FDA-approved labeling.’’. 
15
(2) EFFECTIVE DATE.—The amendment made 
16
by this subsection applies with respect to plan years 
17
beginning on or after the date that is 30 days after 
18
the date of the enactment of this Act. 
19
Æ 
00:37 Dec 17, 2021
H6160
